Proteins that have evolved resistance mutations to targeted therapies are considered suitable PROTAC targets, and the design of specific PROTAC molecules against mutant EGFR proteins in EGFR mutant-driven NSCLC may be a promising strategy to eradicate the occurrence of secondary mutations. Here, EGFR is linked to non-small cell lung carcinoma.